Evidence map›Paper›PMID 27275926›Full record

Trial reportPloS one2016

Novel Dielectric Coagulometer Identifies Hypercoagulability in Patients with a High CHADS2 Score without Atrial Fibrillation.

Yuki Hasegawa, Satomi Hamada, Takuro Nishimura, Takeshi Sasaki, Yusuke Ebana, Mihoko Kawabata, Masahiko Goya, Mitsuaki Isobe, Takatoshi Koyama, Tetsushi Furukawa and 2 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuki HasegawaDepartment of Biofunctional Informatics, Tokyo Medical and Dental University, Tokyo, Japan.
Satomi HamadaDepartment of Biofunctional Informatics, Tokyo Medical and Dental University, Tokyo, Japan.
Takuro NishimuraDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Takeshi SasakiDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Yusuke EbanaDepartment of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Mihoko KawabataDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Masahiko GoyaDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Mitsuaki IsobeDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Takatoshi KoyamaDepartment of Laboratory Molecular Genetics of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
Tetsushi FurukawaDepartment of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
Kenzo HiraoHeart Rhythm Center, Tokyo Medical and Dental University, Tokyo, Japan.
Tetsuo SasanoDepartment of Biofunctional Informatics, Tokyo Medical and Dental University, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3582-6104

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent reports showed that the CHADS2 score predicted the risk of strokes in patients without atrial fibrillation (AF). Although the hypercoagulability may contribute to the thrombogenesis, it has not been fully investigated due to a lack of a sensitive evaluation modality. Recently a novel dielectric blood coagulometry (DBCM) was invented for evaluating the coagulability by measuring the temporal change in whole blood dielectric permittivity.

objectiveWe evaluated the utility of the DBCM for identifying the coagulability. PATIENTS/

methodsFor fundamental experiments, 133 citrated blood samples were drawn from subjects with or without heparin administration. A DBCM analysis was performed to find the adequate coagulation index, and to delineate its measurement range by adding recombinant human tissue factor (TF) or heparin. Then the coagulability was assessed by DBCM and conventional coagulation assays in 84 subjects without AF, who were divided into 3 groups by their CHADS2 score. Another 17 patients who received warfarin were also assessed by DBCM to evaluate the effect of anticoagulants. RESULTS AND

conclusionsWe calculated the derivative of the dielectric permittivity change after recalcification, and extracted the end of acceleration time (EAT) as a novel index. The EAT showed a dose-dependent shortening with the addition of serial dilutions of TF (×10-2 to ×10-4), and a dose-dependent prolongation with the addition of heparin (0.05 to 0.15 U/ml). The EAT was significantly shorter in the higher CHADS2 score group (19.8 ± 4.8, 18.6 ± 3.1, and 16.3 ± 2.7 min in the CHADS2 = 0, 1, and ≥2 groups, respectively, p = 0.0065 by ANOVA). Patients receiving warfarin had a significantly more prolonged EAT than those without warfarin (18.6±4.2 vs. 25.8±7.3 min, p <0.001). DBCM detected the whole blood coagulability with a high sensitivity. Subjects with higher CHADS2 scores exhibited hypercoagulability without AF.

Indexed as

AdultAgedAtrial FibrillationBlood Coagulation TestsFemaleHumansMaleMiddle AgedThrombophilia

Identifiers

PMID27275926
PMCPMC4898832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.